7.20
-0.3(-4.00%)
Currency In USD
| Previous Close | 7.5 |
| Open | 7.5 |
| Day High | 7.5 |
| Day Low | 6.95 |
| 52-Week High | 34.11 |
| 52-Week Low | 5.9 |
| Volume | 1.89M |
| Average Volume | 3.01M |
| Market Cap | 525.54M |
| PE | -10.91 |
| EPS | -0.66 |
| Moving Average 50 Days | 7.45 |
| Moving Average 200 Days | 18.28 |
| Change | -0.3 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $448.6 as of June 01, 2025 at a share price of $7.2. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $216.74 as of June 01, 2025 at a share price of $7.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was g
Arvinas to Present at Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 30, 2025 11:00 AM GMT
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will participate
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review fir